Roivant Sciences

Medallion provides a network management platform for the healthcare industry. Its all-in-one licensing, credentialing, and payer enrollment platform gets rid of the logistical headaches that all too often eat up valuable time and energy. The company was founded in 2020 by Derek Lo and is headquartered in San Francisco, California, United States.

Gen-t is a platform capable of providing the map of genomic research. Gen-t was founded in 2021 and was headquartered in Sao Paulo, Brazil.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

Silicon Therapeutics is a fully integrated drug design, research, and development company. Their multi-disciplinary team is advancing a paradigm shift in biotechnology by pioneering a physics-driven approach to drug design that is tightly coupled to chemistry and biology R&D. Their unique platform is purpose-built to develop novel small molecule therapeutics to address biologically and genetically validated, but previously intractable, protein targets.

Datavant is a health data platform company. We make the world’s health data secure, accessible, and usable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners. To learn more about Datavant, visit datavant.com.

Datavant is a health data platform company. We make the world’s health data secure, accessible, and usable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners. To learn more about Datavant, visit datavant.com.

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. They are developing a portfolio of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.